Pliant Therapeutics Reports Promising Interim Data for PLN-101095.
ByAinvest
Thursday, Dec 4, 2025 7:36 am ET1min read
PLRX--
Pliant Therapeutics reported interim data from its Phase 1 trial evaluating PLN-101095, a dual selective inhibitor of αvβ8 and αvβ1, in combination with pembrolizumab for ICI-refractory advanced or metastatic solid tumors. The data showed one complete response and three partial responses in heavily pretreated patients. The company plans to initiate a Phase 1b expansion trial in 2026, supported by its strong cash position, which is expected to last through 2028.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet